article thumbnail

New FDA guidance on addressing misinformation under White House review

Agency IQ

BY LAURA DIANGELO, MPH A new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products is currently under administrative review at the White House’s Office of Information and Regulatory Affairs (OIRA). Fill out the form to read the full article.

FDA 59
article thumbnail

Prehearing Ruling Establishes Marijuana Rescheduling Hearing Ground Rules

FDA Law Blog: Biosimilars

The purpose of the public hearing is to receive factual evidence and expert opinion testimony on whether marijuana should be rescheduled to schedule III. Parties will have ninety minutes to present the testimony of their witness. Prehearing Ruling (Dec. 4, 2024), at 1.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bogus ‘Cure’ Claims Have U.S. Consumers Snapping Up CBD Products

The Pharma Data

A random sample of 376 posts labeled testimonials found that 90% cited using CBD to treat diagnosable medical conditions. Nearly two-thirds of the testimonials discussed its use for treating mental or emotional problems. Nearly two-thirds of the testimonials discussed its use for treating mental or emotional problems.

article thumbnail

Analysis Chemical Thank You Senate hearing on hazardous substance listing for PFAS finds common ground, but disagreements on implementation tactics

Agency IQ

The testimony of witnesses and the Senators themselves largely agreed on the designation, but diverged on questions of liability exemptions. How the agency plans to regulate PFAS via CERCLA In late 2021, the EPA published the PFAS Strategic Roadmap , which laid out the planned PFAS strategy for the agency between 2021 and 2024.

article thumbnail

Analysis Life Sciences Thank You The 51 regulations that FDA is currently working on

Agency IQ

The 51 regulations that FDA is currently working on The FDA today unveiled its much-anticipated Spring 2023 Unified Agenda, a document outlining the regulations the agency plans to release in 2023 and beyond. The anticipated date of publication is June 2023, meaning we should see this regulation imminently.

article thumbnail

The Growing Trend of Patient-Led Clinical Research in Rare Disease

Conversations in Drug Development Trends

Through relationship-building and increased engagement, regulators aim to improve their understanding of the ‘lived experience’ of patients with rare diseases and hear their top concerns. For example, Voice of the Patient and Patient-Focused Drug Development meetings are focused on one disease or a group of similar diseases.

article thumbnail

Analysis Chemical Thank You Freedhoff testifies in front of Senate EPW over TSCA implementation

Agency IQ

SHELLEY MOORE CAPITO (R-WV) opened the testimony. Carper noted that the issues with how the EPA has implemented TSCA has led to “grievances” from both the chemical industry and environmental advocates, as the flow of chemicals to market and regulation of harmful chemicals has slowed. Opening Sen. TOM CARPER (D-DE) and Sen.